Rational combinations of enzastaurin with novel targeted agents for patients with B-cell non-Hodgkin's lymphoma

Author： Civallero Monica Cosenza Maria Bari Alessia Sacchi Stefano

ISSN： 1354-3784

Source： Expert Opinion on Investigational Drugs, Vol.20, Iss.8, 2011-08, pp. : 1029-1031

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

New agents and approaches to the treatment of B-cell non-Hodgkin lymphoma

By Burton Jack D Goldenberg David M

Expert Opinion on Emerging Drugs, Vol. 15, Iss. 4, 2010-12 ,pp. : 569-583

Informa Healthcare

Access to resources Recommend Favorite

Risk factors for developing infusion reaction after rituximab administration in patients with B-cell non-Hodgkin's lymphoma

By Tachi T. Yasuda M. Usui K. Umeda M. Nagaya K. Osawa T. Ichihashi A. Noguchi Y. Goto H. Kasahara S. Takahashi T. Goto C. Teramachi H.

Die Pharmazie - An International Journal of Pharmaceutical Sciences, Vol. 70, Iss. 10, 2015-10 ,pp. : 674-677

Govi-Verlag

Access to resources Recommend Favorite

Oncologic, Endocrine & Metabolic Emerging drugs in B-cell non-Hodgkin's lymphoma

By Kassam Shireen Montoto Silvia

Expert Opinion on Emerging Drugs, Vol. 13, Iss. 2, 2008-06 ,pp. : 323-343

Informa Healthcare

Access to resources Recommend Favorite

Novel agents for diffuse large B-cell lymphoma

By Sinha Rajni DeJoubner Nutan Flowers Christopher

Expert Opinion on Investigational Drugs, Vol. 20, Iss. 5, 2011-05 ,pp. : 669-680

Informa Healthcare

Access to resources Recommend Favorite

A phase 2 study of weekly temsirolimus and bortezomib for relapsed or refractory B-cell non-Hodgkin lymphoma: A Wisconsin Oncology Network study

Cancer, Vol. 121, Iss. 19, 2015-10 ,pp. : 3465-3471

Blackwell Publishing

Access to resources Recommend Favorite